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 Facts 
 Allergic Diseases 
 General Burden and Prevalence 
 Allergic diseases, including respiratory allergy, skin 
diseases, and adverse reactions to drugs and foods, rep-
resent a major burden from both an epidemiological and 
an economical point of view. 
 Respiratory Allergies. As summarized in the World Al-
lergy Organization (WAO) White Book  [1] and according 
to ISAAC (International Study of Asthma and Allergies 
in Childhood) data  [2] , the worldwide prevalence of rhi-
noconjunctivitis ranges from 20 to 35%, and that of asth-
ma from 10 to 20%. Respiratory allergies are of particular 
importance, mainly due to their high prevalence and 
their socioeconomic impact. In fact, those diseases are 
chronic in nature and therefore require long-term treat-
ment. In addition, they induce substantial indirect costs 
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 Abstract 
 Aims of the Monaco Charter: (1) to present the current evi-
dence on the efficacy and safety of allergen-specific immu-
notherapy (SIT) and to address the reasons for its underuse 
in clinical practice; (2) to develop strategies to increase the 
awareness about the benefits and the hazards of SIT in aller-
gic patients, lay public and healthcare professionals not 
trained  in allergy, and (3) to make SIT accessible and afford-
able to eligible patients.  Copyright © 2012 S. Karger AG, Basel 
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due to loss of productivity (work and school absenteeism) 
 [3, 4] . This holds true for both asthma and rhinitis. Fi-
nally, asthma and rhinitis often coexist and involve the 
same immunological mechanisms. Allergic rhinitis is a 
risk factor for the subsequent development of asthma  [5] .
 Non-Respiratory Allergies. In addition to respiratory 
allergy, non-respiratory allergic diseases have a very high 
prevalence, e.g. atopic eczema (20%) or urticaria (15–
20%). Despite their lower prevalence, food allergy (3–5%), 
anaphylaxis (0.1%) or insect venom hypersensitivity (1%) 
also pose a significant economic burden due to morbid-
ity, hospitalization and critical care resources utiliza-
tion  [1] .
 According to an official statement of the Council of 
the European Union, the leading priority is to reduce 
health inequalities  [6] .
Allergen-Specific Immunotherapy
 Allergen-specific immunotherapy (SIT) represents a 
unique modality of treatment for respiratory allergies. SIT 
acts not only as symptomatic treatment, but also as a bio-
logical response modifier, which changes profoundly and 
specifically the immunological response to allergens  [7, 8] . 
 Treatment Routes and Effects.  Numerous controlled 
trials and meta-analyses revealed that SIT, administered 
either subcutaneously or sublingually, significantly re-
duces the symptoms of allergic rhinitis and asthma  [9–
11] . The reduction in symptoms consequently results in a 
reduced need for symptomatic medications. 
 Mechanisms of Action. Because of its special mecha-
nisms of action, SIT possesses some effects not shared by 
pharmacological treatments, such as the persistence of 
the clinical benefit years after SIT discontinuation and 
the reduction in the risk of asthma development  [12] . 
Those ‘additional’ actions of SIT have an important so-
cioeconomic effect (i.e. reduction in disease costs in the 
long term), which has been formally demonstrated in 
specific studies  [13, 14] . SIT can be considered a ‘pheno-
type-oriented’ treatment that is effective in carefully se-
lected patients with IgE-mediated allergy in whom the 
causal role of the allergen(s) in eliciting symptoms is 
properly demonstrated. 
 Prerequisites.  The prescription of SIT requires a de-
tailed and accurate diagnosis to clearly identify the 
allergen(s) for which desensitization is instituted  [15] . 
This is mandatory for a successful treatment. 
 Treating Physicians. In general, SIT is mainly prescribed 
and managed by allergists, but other specialists (pulmon-
ologists, ENT specialists, pediatricians and dermatolo-
gists) are also involved in some countries  [16] . Despite this, 
the presence of allergists seems to be largely insufficient in 
this specific field of immunotherapy, as shown by a recent 
European survey  [17] , and SIT is poorly known by the gen-
eral population  [18] . Finally, general practitioners (GPs) 
play a significant role, since patients often first refer to GPs: 
they decide the diagnostic procedures and are in charge of 
the follow-up of patients receiving SIT  [1] .
 Barriers 
 Barriers to the Use of SIT and Unmet Needs 
 Several international documents, such as the WAO 
SLIT Position Paper  [10] , report the unmet needs about 
the scientific aspects of SIT. These include methodologi-
cal shortcomings, bias in clinical trials and standardiza-
tion. We herein focus on important additional issues 
and real barriers to the approriate dissemination of SIT, 
which can be summarized in the following items: 
 • Underappreciation of the science supporting SIT 
 • Complexity and time consumption in performing ap-
propriate SIT studies compared to clinical trials with 
drugs 
 • Absence of reimbursement of SIT in most countries 
 • Limitation of resources available for SIT promotion 
due to the small size of the manufacturers’ companies. 
 Patients . Currently, over 30% of allergic patients have 
never received a specific allergy diagnostic test. Knowl-
edge about allergen SIT is low overall and varies widely 
by country: in Europe, 30% (country range: 10–52%) had 
never heard of SIT  [18] . These data emphasize the surpris-
ing disparity between burden and awareness of allergic 
disease and its treatment.
 SIT Reimbursement . As mentioned before, this is a 
crucial issue in most countries.
 Promotion of SIT Awareness. Resources available for 
the promotion of SIT awareness remain scarce.
 Underappreciation.  Another major barrier to the use 
of SIT is the underappreciation of the science supporting 
SIT, the efficacy of which (see above) is fully documented. 
This is confirmed by the fact that immunotherapy prod-
ucts are registered by many regulatory agencies. 
 Training . It is still largely insufficient in allergy (train-
ing implies the skills for a correct diagnosis and treat-
ment) in several countries. Given the high prevalence of 
respiratory allergies, some forms of allergy training must 
be considered as an essential part of the general profes-
sional training for physicians, specialists and GPs  [19, 20] . 
 Education in Allergic Diseases. It is largely insufficient 
in many countries also among pharmacists  [21] .
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 Strategies 
 Strategies to Improve Awareness and Dissemination 
 Patients’ Associations . They should/could play a cru-
cial role in implementing the knowledge/awareness of an 
updated allergy diagnosis and they should associate with 
medical associations to obtain reimbursement of the 
treatment.
 General Practitioners . The possibility to create a co-
hort of GPs with a special interest in allergy and with the 
joint task of developing and providing clinical service in 
primary care should be promoted wherever possible. Col-
laboration between primary care teams and allergists 
should become a social priority in this field  [22, 23] .
 Proper Documentation. Documentation and instruc-
tions from the prescribing allergist’s office as well as 
forms designed for complete and accurate documenta-
tion of therapy are vital components of safe administra-
tion. In addition, proper educational programs designed 
to raise skills in SIT within their community are re-
quired.
 Patient Leaflets. A proper leaflet containing synthet-
ic key information on allergy and SIT should be pre-
pared in collaboration with patient organizations. This 
tool should be translated into different languages and 
promoted through media by patient organization cam-
paigns, and distributed in doctors’ offices and pharma-
cies.
 Educational Programs. These initiatives should be fi-
nalized to GP, pharmacist and healthcare professional 
education. SIT guidelines (with pocket versions) for GPs 
and pharmacists should be prepared by their own scien-
tific organizations in cooperation with specialists. Post-
graduate schools and masters on SIT should be promoted 
by the allergy scientific societies.
 Regulatory Authorities. Currently, allergic diseases 
and SIT are considered in most of the regional and na-
tional drug agencies. Allergen standardization is promot-
ed and requested. Harmonization of regulations among 
countries is needed. Scientific societies should partner, at 
any level, to advise and promote this process.
 Dissemination Strategy of the Monaco Charter and 
Related Documents  
 Target Population: Physicians and Pharmacists  
 Publication of the Monaco Charter  
 Congress Events. The aim should be to focus on the 
importance of curing allergies and not just to treat symp-
toms. The organization should be run by the GP scien-
tific organizations (CME activities should also be part of 
the project).
 Media Campaigns and Publications in GP/Pharmacist 
Journals. SIT information should be disseminated 
through internet websites and blogs of GPs and/or phar-
macists. At present, information on SIT is missing on the 
vast majority of these websites worldwide. Communica-
tion in journals dedicated to GPs and pharmacists com-
bined with media campaigns in lay press could help to 
achieve three goals: 
 (1) GPs and pharmacists will improve their skills 
(awareness/knowledge) in SIT.
 (2) GPs and pharmacists will be less reluctant to con-
sider SIT prescriptions to allergic patients.
(3) Allergic patients will be more aware of SIT, and de-
manding it to GPs and pharmacists, because of the con-
comitant media campaign. 
 Websites. Websites of GPs’ (primary care practitioners 
and family practitioners) organizations and pharmacists 
should contain essential news about SIT. Links to other 
websites (e.g. manufacturers, allergy societies, patient or-
ganizations and educational sites) should be created.
 Target Population: Allergic Patients and the General 
Population 
 Publication of the Monaco Charter  
 It is crucial to transmit simple and clear messages in 
the media (via radio, TV, newspapers and magazines, for 
example) to impose an effect on the public opinion. For 
instance, the importance of causal allergens should be 
stressed in order to focus on the possibility to treat the 
disease and not ‘just’ the symptoms.
 SIT safety and clear messages require special emphasis:
Reassurance of the Targets about SIT Safety
 General concern about SIT safety is still a barrier to its 
use in certain countries and/or regions; therefore, strate-
gies to overcome this barrier should be developed.
 Clear, Simple and Straight Messages about SIT
Effectiveness 
 Lay press is a major tool to spread messages, and, in 
certain countries, special focus should be placed on wom-
en’s magazine, whose influence in the public arena is re-
markable. The same role, possibly even more impacting, 
is nowadays played by blogs: the women’s ones and the 
mothers’ ones, which are formidable and successful ‘by 
word of mouth’ (network of information).
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 Leaflet Distribution: Leaflets created for the pharma-
cies and doctors’ offices can be easily added as supple-
ment to the weekly/monthly magazines dedicated to 
health or women, or magazines of general interest.
 Patients’ Association Blogs.  They should contain and 
implement discussion and awareness on SIT. A warning 
on this: the control of the information to prevent mislead-
ing, incorrect or wrong news has to be considered. Thus, 
competent persons should take the lead and the control 
of these tools/initiatives.
 Social Networks (e.g. Facebook or Twitter). A group 
called ‘Allergen-Specific Immunotherapy Friends’ or ‘I 
Like Allergen-Specific Immunotherapy’ can be created 
and led by national or international opinion leaders. 
 Consequently, allergic patients will be more aware of 
SIT, and ask their GPs and pharmacists for SIT, because 
of the media campaign.
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